Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of 68.12 RMB based on a 2025 PE of 60X, which is slightly discounted compared to peers due to stable operations [5][9]. Core Insights - The company's revenue continues to grow rapidly, with domestic demand gradually recovering. The introduction of new products in the R&D pipeline is expected to open up additional demand opportunities [2][5]. - In the first half of 2025, the company achieved a revenue of 387 million RMB, representing a year-on-year increase of 29.38%. The net profit attributable to shareholders was 83.80 million RMB, up 47.81% [5][9]. - The domestic revenue reached 123 million RMB, reflecting a growth of 36.65%, while overseas revenue was 258 million RMB, increasing by 22.94% [5][9]. - The company has effectively controlled its expense ratios, leading to improved profitability. The gross profit margin for the first half of 2025 was 90.14%, and the net profit margin was 21.53%, an increase of 3.59 percentage points year-on-year [5][9]. Financial Summary - The financial summary indicates a strong growth trajectory, with total revenue projected to reach 840 million RMB in 2025, up 30.2% from the previous year. Net profit attributable to shareholders is expected to be 191 million RMB, a 53.9% increase [4][6]. - The company has increased its R&D investment, expanding its team to 279 personnel and diversifying its product offerings, with over 5000 products sold [5][9]. - The report highlights the successful development of nearly 50 GMP-grade products in the CGT field and a range of high-quality products in the ADC field [5][9].
百普赛斯（301080）：国内业务强势复苏，海外业务保持稳健